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Abstract
The author reports herein a case of occult very small lung carcinoma with a solitary brain
metastasis that is clinically diagnosed as cavernous hemangioma, with an emphasis on pathologic
findings. A 48-year-old Japanese man was admitted to our hospital complaining of mild paresis of left
leg. Brain CT and MRI showed a solitary tumor (2 cm) with features of cavernous hemangioma in the
right temporal lobe. Tumorectomy was performed, and it was pathologically undifferentiated
carcinoma. An immunohistochemical analysis reveled that the carcinoma cells were positive for four
types of pancytokeratin, cytokeratin (CK) 5/6, CK7, CK18, CK19, p63, and Ki-67 (78%). They were
negative for high molecular weight CK, CK14, CK20, TTF-1, PE-10, melanosome, S100 protein, EMA,
vimentin, CD34, myoglobin, CEA, p53, desmin, a-smooth muscle actin, chromogranin, synapto-
physin, CD56, neuron-specific enolase, CD68, KIT, and PDGFRA. The positive CK7 and negative
CK20 suggested lung origin, and cytokeratin profiles and positive CK5/6 and p63 suggested a
squamous differentiation. The pathological diagnosis was undifferentiated carcinoma with squamous
differentiation probably of lung origin. Later, systemic CT, MRI and PET were performed, and they
detected a small lung tumor (8 mm) in the right apex. The lung biopsy revealed an undifferentiated
carcinoma with focal squamous differentiation; the immunohistochemical findings were the same as
those of the brain tumor. These findings suggest that occult very small lung carcinoma can metastasize
to brain and such a metastasis may mimic cavernous hemangioma radiologically. Pathologic
observations using many antibodies are very useful to determine the origin and histological type in
solitary brain nodule.
Introduction
Brain metastasis of lung carcinoma is common. In the
majority of such an event, lung tumor was first recognized,
and brain metastasis develops later. Lung cancer with a fist
manifestation of brain metastasis is relatively rare [1,2]. In
addition, occult very tiny lung cancer <10 mm with a first
manifestation of solitary brain metastasis is rare [1,2].
A solitary small brain mass lesion is difficult to diagnose
correctly. The important points of differential diagnosis
are the density of the lesion, contour of the lesion, and
edema of surrounding tissue.
In general, determination of the origin of metastatic malig-
nancies is difficult pathologically. Immunohistochemistry
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antibodiesareafew(suchasPSAforprostaticcarcinoma),a
panel of antibodies are used. Nevertheless, determination
of the origin and histological type are frequently difficult.
The author herein reports a case of occult very small lung
carcinoma presenting as a small solitary brain tumor that
was clinically diagnosed as primary brain cavernous
hemangioma. Pathological and immunohistochemical
examinations revealed that the lesion was metastatic
undifferentiated carcinoma with squamous differentiation,
and could determine the origin and histological type of the
braintumor.Later,systemicCT,MRIandPETrevealedavery
small lung lesion, biopsy of which showed an undiffer-
entiated lung carcinoma with squamous differentiation.
Case presentation
A 48-year-old Japanese man presented as mild paresis of
left leg, and admitted to our hospital for scrutiny. Brain CT
and MRI showed a solitary tumor (2 cm) with features of
cavernous hemangioma in the right temporal lobe
(Figure 1). The tumor was solitary and well defined. No
infiltrative growth was recognized. The density was that of
blood. No edema was seen in the surrounding brain. The
radiological diagnosis was primary brain cavernous
hemangioma. A tumorectomy was performed, and it
revealed an undifferentiated carcinoma without differen-
tiation on HE sections (Figure 2).
An immunohistochemical analysis was performed using
Dako Envision method (Dako Corp. Glostrup, Denmark),
as previously described [3-7]. The immnunohistochemical
reagents and results are shown in (Table 1). The immuno-
histochemistry reveled that the carcinoma cells were
positive for four types of pancytokeratins, cytokeratin
(CK) 5/6 (Figure 3), CK7 (Figure 4), CK18, CK19, p63
(Figure 5), and Ki-67 (labeling = 78%). They were negative
for high molecular weight CK, CK14, CK20, TTF-1, PE10.
melanosome, S100 protein, EMA, vimentin, CD34, myo-
globin, CEA, p53, desmin, a-smooth muscle actin,
chromogranin, synaptophysin, CD56, neuron-specific
enolase, CD68, KIT, and PDGFRA.
The positive CK7 and negative CK20 suggested a lung
origin, and the cytokeratin profiles and positive CK5/6 and
p63 suggested a squamous differentiation. The pathologi-
cal diagnosis was undifferentiated carcinoma with squa-
mous differentiation probably of lung origin.
Later, systemic CT, MRI and PET were performed, and they
detected a small lung tumor (8 mm) in the right apex
(Figure 6). The lung biopsy revealed an undifferentiated
carcinoma with focal squamous differentiation (Figure 7);
the immunohistochemical findings were almost the same
as those of the brain tumor (Table 1).
Figure 1. Brain CT. A solitary tumorous lesion (2 cm) is
seen in the right temporal lobe. The tumor was solitary
and well defined. No infiltrative growth was recognized.
The density was that of blood. No edema was seen in the
surrounding brain. The ridiologists’ diagnosis was cavernous
hemanigioma.
Figure 2. Histology of the brain tumor. Undifferentiated
carcinomatous tissue is seen. The tumor cells were round and
have hyperchromatic vesicular nuclei. Mitotic and apoptotic
figures are scattered. No differentiation is seen. The
pathological diagnosis was undifferentiated carcinoma.
HE, ×100.
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In the present case, the brain lesion was solitary and was
clinically diagnosed as cavernous hemangioma based on
the density, contour, and the absence of edema and
invasive features which are findings of cavernous heman-
gioma [8]. These findings indicate that the metastatic lung
carcinoma may mimic cavernous hemangioma of the
brain radiologically. The author is experimental liver
pathologist, and does not have enough knowledge of CT
and MRI diagnosis. After the pathologic diagnosis of
metastatic undifferentiated carcinoma, the author dis-
cussed radiologists the nature of brain shadow. They
claimed that the lesion was solitary and well defined, and
had the density of blood or hematoma No edema or
invasive features were absent. Their retrospective diagnosis
was also that of cavernous hemangioma. However, they
regretted that metastatic carcinoma might show such a
cavernous hemangioma-like shadow. The misdiagnosis of
radiologists may be due to the difficulty in the interpreta-
tion of the shadow.
In the present study, the author examined 33 antibodies.
The author myself performed these the large number of
immunohistochemical staining not only for practical use
but also for academic interest. In general, anti-pancytoker-
atins AE1/3 and CAM5.2 were adequate. The both
antibodies detect wide ranges of cytokeratin. The author
stained polyclonal and tibody and KL-1 for academic
interest. High-molecular weigh cytokeratin (34bE12) and
CK5/6 cover squamous epithelium. CK5/6 is used from
distinction from mesothelioma. CK7/CK20 patterns were
widely used as diagnostic pathology. The use of CK14 was
of academic interest, but CK14 is useful in esophageal
squamous cell carcinoma. The use of CK18 and CK19 was
of academic interest, but these were used for distinction
from pancreaticobiliary carcinoma. PE10 and TTF-1 were
used as markers of adenocarcinoma of the lung. Melano-
some and S100 protein were used from differentiation
from epithelioid malignant melanoma. EMA and CKs
were used to determine the epithelial nature of the
tumor. The mesenchymal markers including vimentin,
Table 1. Immunohistochemical reagents and results
Antigens Antibodies (clone) Sources Results
Brain Lung
Pancytokeratin AE1/3 Dako Corp. Glostrup, Denmark +++ +++
Pancytokeratin polyclonal wide Dako +++ +++
Pancytokeratin KL-1 Immunotech, Marseille, France +++ +++
Pancytokeratin CAM5.2 Bekton-Dicckinson, CA, USA +++ +++
HMWCK 34bE12 Dako --
CK5/6 D5/16 Dako +++ +++
CK7 N1626 Dako ++ +++
CK14 LL002 Novocastra, Newcastle upon type, UK --
CK 18 DC10 Dako + ++
CK 19 RCK 108 Progen, Heidelberg, Germany + ++
CK20 K20.8 Dako --
TTF-1 8G7G3/1 Dako --
Surfactant protein PE-10 Dako --
Melanosome HMB45 Dako --
EMA E29 Dako --
Vimentin Vim 3B4 Dako --
Myoglobin polyclonal Dako --
CEA polyclonal Dako --
Desmin D33 Dako --
S100 protein polyclonal Dako --
CA19-9 NS19-9 TFB Lab, Tokyo, Japan --
ASMA 1A4 Dako --
CD34 NU-4A1 Nichirei, Tokyo, Japn --
p53 protein DO-7 Dako --
p63 4A4 Dako +++ +++
Ki-67 MIB-I Dako 78% 62%
Chromogranin DAK-A3 Dako --
Synaptophysin Polyconal Dako --
NSE BBS/NC/VI-H14 Dako --
CD56 UJ13A Dako --
CD68 KP-1 Dako --
KIT polyclonal Dako --
PDGFRA polyclonal Santa Cruz, CA, USA --
+++,67-100%positive;++,33-66%;+,1-33%positive;-,negative;HMWCK,highmolecularweightcytokerain;CK,cytokeratin;TTF-1,thyroidtranscriptional
factor-1; EMA, epithelial membrane antigen; CEA, carcinoembryonic antigen; ASMA, a-smooth muscle antigen; NSE, neuron-specific enolase; PDGFRA,
platelet-derived growth factor receptor-a.
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actin, CD34, and CD68 were used for differentiation
from carcinomatoid sarcoma. P63 was used for squamous
a n dt r a n s i t i o n a lc e l lc a r c i n o m a .C E Aw a su s e df o r
differentiation from poorly differentiated adenocarci-
noma. P53 and Ki-67 was used for the malignant nature
of the tumor and for the proliferative fraction. Chromo-
granin, synaptophysin, CD56, neuron-specific enolase
were used to determine the neuroendocrine features of
tumor cells. KIT and PDGFRA were used for neuroendo-
cine carcinoma as well as some particular neoplasm. The
author stained KIT and PDGFRA, because the author has
investigated these molecules and mutational status of
these genes.
The brain tumor was pathologically metastatic undiffer-
entiated carcinoma on HE sections in the present case.
Immunohistochemically, the tumor was positive for p63,
various types of cytokeratin, CK 5/6, suggesting that the
Figure 4. Cytokeratin 7 is strongly expressed in the
cytoplasm of the brain tumor. ×100.
Figure 5. p63 is strongly and diffusely expressed in the nuclei
of the brain tumor. ×100.
Figure 3. Cytokeratin 5/6 is strongly expressed in the
cytoplasm of the brain tumor. ×100.
Figure 6. Chest CT. A very small tumor (8 mm) is seen in the
right lung apex. The tumor shows irregular contours and
invades the pleura.
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immunoreactions for TTF-1 and PE10 suggest that the
tumor had no adenocarcinomatous differentiation [9-11].
The absence of neuroendocrine antigens (chromogranin,
synaptophysin, CD56, neuron-specific enolase) suggests
that the brain tumor was not neuroendocrine carcinoma
such as large neuroendocrine carcinoma. Thus, the author
could determine the histological type of the present brain
tumor.
The majority of solitary metastasis of brain tumor was lung
cancer, gastrointestinal cancers, and breast cancers [12]. In
the present study, the CK7 and CK20 pattern suggested a
lung cancer together with squamous nature of the tumor
[13,14]. Considering the frequency of metastatic brain
tumor and the present immunohistochemical study, the
author could suggest that the tumor was lung undiffer-
entiated adenocarcinoma with squamous differentiation.
In fact, later imaging modalities detected a very small
occult lung cancer (8 mm) in the right apex. The lung
tumor was found to have the same histology and
immunohistochemical findings as the brain tumor. There-
fore, the present case was diagnosed as a occult lung
carcinoma with a solitary brain metastasis.
In summary, the present case suggests that an extensive
immunohistochemical investigation can determine histo-
logical type and origin in a solitary metastatic brain cancer.
In addition, it was suggested that occult very small lung
carcinoma can metastasize to brain and such a metastasis
may mimic cavernous hemangioma radiologically. Patho-
logic observations using many antibodies are very useful
to determine the origin and histological type in solitary
brain nodule.
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